case_images: PMC6538880_01
case_images: (A) Histology of primary carcinoma ex pleomorphic adenoma; (B) Immunohistochemistry showed that tumor cells were positive for CK8/18. (C) Immunohistochemistry showed that Ki 67 was 30-40%. (D) Histology of pulmonary metastasis. (E) Immunohistochemistry showed that tumor cells were positive for CK8/18. (F) Immunohistochemistry showed that Ki 67 was about 70%. (A-F) Original magnification, x100, (A-C: primary carcinoma ex pleomorphic adenoma of the submandibular gland, D-F: pulmonary metastasis, A and D: hematoxylin-eosin).
case_images: OTT-12-4093-g0001.jpg
case_images: PMC6538880_01_OTT-12-4093-g0001.jpg
case_images: F0001
case_images: Ki-67 proliferation index was 30-40%. (Figure 1A-C) No metastasis to the lymph nodes in the neck was found. Ki67 was about 70% (Figure 1D-F).
case_images: Chest CT scans before and after anlotinib treatment. (A and D): Before anlotinib treatment, two measurable tumor lesions were shown. (B and E) After two cycles of anlotinib treatment, a Partial response was observed. (C and F) After six cycles of anlotinib treatment, a continued partial response was observed. The white and black arrowheads aim at two measurable tumor lesions, respectively. Response assessment was based on RECIST guideline version 1.1.
case_images: OTT-12-4093-g0002.jpg
case_images: PMC6538880_01_OTT-12-4093-g0002.jpg
case_images: F0002
case_images: As shown in Figure 2, partial response was observed after two cycles of treatment.